☆ 4.6 Article

Thrombosis in multiple myeloma: Risk estimation by induction regimen and association with overall survival

AMERICAN JOURNAL OF HEMATOLOGY (2023)

Related references

Note: Only part of the references are listed.

Article Oncology

Mortality trends in multiple myeloma after the introduction of novel therapies in the United States

Moritz Binder et al.

Summary: Recent advancements in disease biology, drug development, and supportive care have led to improved outcomes in multiple myeloma patients. However, disparities exist in mortality trends among patient populations, with older patients and those with unfavorable disease characteristics experiencing higher excess mortality. Efforts should be made to develop safe and effective therapies for these vulnerable patients and to ensure timely access to specialized care in the community.

LEUKEMIA (2022)

Add to Collection

Article Hematology

Comparison of venous thromboembolism incidence in newly diagnosed multiple myeloma patients receiving bortezomib, lenalidomide, dexamethasone (RVD) or carfilzomib, lenalidomide, dexamethasone (KRD) with aspirin or rivaroxaban thromboprophylaxis

Katrina Piedra et al.

Summary: The incidence of venous thromboembolism varies across different regimens in newly diagnosed multiple myeloma patients, with higher rates seen in those treated with KRD induction. The use of low-dose rivaroxaban thromboprophylaxis can mitigate this risk without an observable increase in bleeding rates.

BRITISH JOURNAL OF HAEMATOLOGY (2022)

Add to Collection

Article Hematology

Multiple myeloma: 2022 update on diagnosis, risk stratification, and management

S. Vincent Rajkumar

Summary: Multiple myeloma is a hematologic malignancy that accounts for approximately 10% of cases. The diagnosis is based on the presence of clonal bone marrow plasma cells and associated symptoms. High-risk patients require stem cell transplantation and may benefit from different treatment regimens.

AMERICAN JOURNAL OF HEMATOLOGY (2022)

Add to Collection

Article Oncology

Thromboembolic events and thromboprophylaxis associated with immunomodulators in multiple myeloma patients: a real-life study

V Leclerc et al.

Summary: This study aimed to evaluate the implementation of international guidelines regarding thromboprophylaxis strategy in myeloma patients treated with immunomodulatory drugs. The results showed that thromboprophylaxis was commonly performed in these patients, but the choice of anticoagulant or anti-platelet agent remained debatable, with variable adherence to existing guidelines.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2022)

Add to Collection

Editorial Material Hematology

Safety and efficacy of apixaban as thromboprophylaxis in myeloma patients receiving chemotherapy: A prospective cohort study

Zara Sayar et al.

THROMBOSIS RESEARCH (2022)

Add to Collection

Article Cardiac & Cardiovascular Systems

Venous thromboembolism prophylaxis in patients with multiple myeloma: where are we and where are we going?

Gianfranco Lapietra et al.

Summary: Venous thromboembolism is a common complication in patients with hematologic malignancies, particularly multiple myeloma patients. Current guidelines for prevention are lacking and there is a debate on whether to stratify thrombotic risk or provide prophylactic treatment regardless of risk factors. New studies on direct oral anticoagulants in myeloma patients are promising but larger trials are needed for confirmation. An international consensus on best prophylaxis is still missing, leaving thrombosis in multiple myeloma as an ongoing issue.

JOURNAL OF THROMBOSIS AND THROMBOLYSIS (2021)

Add to Collection

Article Oncology

Thromboembolism Incidence and Risk Factors in Multiple Myeloma After First Exposure to Immunomodulatory Drug-Based Regimens

Jai N. Patel et al.

Summary: Male gender and presence of any comorbidity were associated with time to thromboembolism in multiple myeloma patients. Despite a higher proportion of patients with comorbidities in the anticoagulant group, there were no differences in thromboembolism incidence among different thromboprophylaxis types.

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2021)

Add to Collection

Article Hematology

Validation of the IMPEDE VTE score for prediction of venous thromboembolism in multiple myeloma: a retrospective cohort study

Fahrettin Covut et al.

Summary: The IMPEDE VTE score is a novel risk prediction tool for venous thromboembolism in multiple myeloma patients, with validated predictive ability for VTE occurrence within 6 months. The study found that patients in the low risk group had lower incidence of VTE, while those in the intermediate and high risk groups had higher rates, and a higher ECOG performance status was associated with VTE occurrence. Other MM characteristics such as stage, immunoglobulin subtype, and cytogenetics were not predictors of VTE.

BRITISH JOURNAL OF HAEMATOLOGY (2021)

Add to Collection

Letter Oncology

Arterial thromboembolism in multiple myeloma in the context of modern anti-myeloma therapy

Rajshekhar Chakraborty et al.

BLOOD CANCER JOURNAL (2021)

Add to Collection

Review Oncology

Venous thromboembolism risk with contemporary lenalidomide-based regimens despite thromboprophylaxis in multiple myeloma: A systematic review and meta-analysis

Rajshekhar Chakraborty et al.

CANCER (2020)

Add to Collection

Review Oncology

Multiple Myeloma and Thrombosis: Prophylaxis and Risk Prediction Tools

Despina Fotiou et al.

CANCERS (2020)

Add to Collection

Article Hematology

Thrombosis in patients with myeloma treated in the Myeloma IX and Myeloma XI phase 3 randomized controlled trials

Charlotte A. Bradbury et al.

BLOOD (2020)

Add to Collection

Article Oncology

Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial

Shaji K. Kumar et al.

LANCET ONCOLOGY (2020)

Add to Collection

Article Hematology

Venous thromboembolism in multiple myeloma is associated with increased mortality

Martin W. Schoen et al.

RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS (2020)

Add to Collection

Letter Hematology

Safety and efficacy of apixaban for routine thromboprophylaxis in myeloma patients treated with thalidomide- and lenalidomide-containing regimens

Neill P. F. Storrar et al.

BRITISH JOURNAL OF HAEMATOLOGY (2019)

Add to Collection

Article Medicine, General & Internal

Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer

A. A. Khorana et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

Add to Collection

Article Oncology

Derivation and Validation of a Risk Assessment Model for Immunomodulatory Drug-Associated Thrombosis Among Patients With Multiple Myeloma

Ang Li et al.

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2019)

Add to Collection

Article Hematology

Predicting venous thromboembolism in multiple myeloma: development and validation of the IMPEDE VTE score

Kristen M. Sanfilippo et al.

AMERICAN JOURNAL OF HEMATOLOGY (2019)

Add to Collection

Article Oncology

Prospective Study of Cardiac Events During Proteasome Inhibitor Therapy for Relapsed Multiple Myeloma

Robert F. Cornell et al.

JOURNAL OF CLINICAL ONCOLOGY (2019)

Add to Collection

Article Medicine, General & Internal

Apixaban to Prevent Venous Thromboembolism in Patients with Cancer

Marc Carrier et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

Add to Collection

Article Hematology

Apixaban for the prevention of thromboembolism in immunomodulatory-treated myeloma patients: Myelaxat, a phase 2 pilot study

Brigitte Pegourie et al.

AMERICAN JOURNAL OF HEMATOLOGY (2019)

Add to Collection

Article Cardiac & Cardiovascular Systems

Use of direct oral anticoagulants in patients on immunomodulatory agents

L. Man et al.

JOURNAL OF THROMBOSIS AND THROMBOLYSIS (2017)

Add to Collection

Article Hematology

Lenalidomide as a novel treatment for refractory acquired von Willebrand syndrome associated with monoclonal gammopathy

M. Lavin et al.

JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2016)

Add to Collection

Article Hematology

Effect of serum monoclonal protein concentration on haemostasis in patients with multiple myeloma

Heyu Huang et al.

BLOOD COAGULATION & FIBRINOLYSIS (2015)

Add to Collection

Article Hematology

European Myeloma Network Guidelines for the Management of Multiple Myeloma-related Complications

Evangelos Terpos et al.

HAEMATOLOGICA (2015)

Add to Collection

Article Hematology

European Myeloma Network Guidelines for the Management of Multiple Myeloma-related Complications

Evangelos Terpos et al.

HAEMATOLOGICA (2015)

Add to Collection

Article Oncology

International Myeloma Working Group Consensus Statement for the Management, Treatment, and Supportive Care of Patients With Myeloma Not Eligible for Standard Autologous Stem-Cell Transplantation

Antonio Palumbo et al.

JOURNAL OF CLINICAL ONCOLOGY (2014)

Add to Collection

Article Hematology

Venous Thromboembolism in Multiple Myeloma

Valerio De Stefano et al.

SEMINARS IN THROMBOSIS AND HEMOSTASIS (2014)

Add to Collection

Article Hematology

Inhibitory effects of bortezomib on platelet aggregation in patients with multiple myeloma

Joanna Rupa-Matysek et al.

THROMBOSIS RESEARCH (2014)

Add to Collection

Article Health Care Sciences & Services

Health care costs associated with venous thromboembolism in selected high-risk ambulatory patients with solid tumors undergoing chemotherapy in the United States

Alok A. Khorana et al.

CLINICOECONOMICS AND OUTCOMES RESEARCH (2013)

Add to Collection

Article Hematology

Hyperviscosity in plasma cell dyscrasias

Hau C. Kwaan

CLINICAL HEMORHEOLOGY AND MICROCIRCULATION (2013)

Add to Collection

Article Hematology

Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide

Alessandra Larocca et al.

BLOOD (2012)

Add to Collection

Article Hematology

Thrombosis is associated with inferior survival in multiple myeloma

Sigurdur Y. Kristinsson et al.

HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)

Add to Collection

Article Hematology

Thrombosis in multiple myeloma (MM)

Gabriela Cesarman-Maus et al.

HEMATOLOGY (2012)

Add to Collection

Article Medicine, General & Internal

Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma

Michel Attal et al.

NEW ENGLAND JOURNAL OF MEDICINE (2012)

Add to Collection

Article Oncology

Aspirin, Warfarin, or Enoxaparin Thromboprophylaxis in Patients With Multiple Myeloma Treated With Thalidomide: A Phase III, Open-Label, Randomized Trial

Antonio Palumbo et al.

JOURNAL OF CLINICAL ONCOLOGY (2011)

Add to Collection

Article Education, Scientific Disciplines

Thrombosis in Multiple Myeloma

Sigurdur Yngvi Kristinsson

HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2010)

Add to Collection

Review Oncology

Venous Thromboembolism in the Hematologic Malignancies

Anna Falanga et al.

JOURNAL OF CLINICAL ONCOLOGY (2009)

Add to Collection

Article Hematology

Deep vein thrombosis after monoclonal gammopathy of undetermined significance and multiple myeloma

Sigurdur Y. Kristinsson et al.

BLOOD (2008)

Add to Collection

© Peeref 2019-2024. All rights reserved.